Clinical trials
Leukemia-Lymphoma, Adult T-Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 4 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 5 |
| Terminated | 4 |
| Active, not recruiting | 3 |
| Suspended | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 8 |
| Kyowa Kirin Co., Ltd. | 3 |
| MP Biomedicals, LLC | 3 |
| Celgene | 2 |
| Kyowa Kirin, Inc. | 2 |
| Actuate Therapeutics Inc. | 1 |
| Bristol-Myers Squibb | 1 |
| Carlos Brites | 1 |
| Chongqing Precision Biotech Co., Ltd | 1 |
| Columbia University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia-Lymphoma, Adult T-Cell | 31 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Lymphoma, T-Cell, Peripheral | 6 |
| HTLV-I Infections | 5 |
| Lymphoma | 5 |
| Lymphoma, T-Cell, Cutaneous | 5 |
| Lymphoma, Non-Hodgkin | 4 |
| Paraparesis, Tropical Spastic | 4 |
| HTLV-II Infections | 3 |
| Immunoblastic Lymphadenopathy | 3 |
Trials
Showing 26 to 31 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.